Explore the words cloud of the InCa project. It provides you a very rough idea of what is the project "InCa" about.
The following table provides information about the project.
EVOSENSE RESEARCH & DEVELOPMENT GMBH
|Coordinator Country||Germany [DE]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
|Duration (year-month-day)||from 2016-12-01 to 2017-04-30|
Take a look of project's partnership.
|1||EVOSENSE RESEARCH & DEVELOPMENT GMBH||DE (DARMSTADT)||coordinator||50˙000.00|
|2||NANOSCALE SYSTEMS, NANOSS GMBH||DE (DARMSTADT)||participant||0.00|
|3||TRINITAS VENTURES LIMITED||IE (DUBLIN)||participant||0.00|
Congestive Heart failure (CHF) affects more than 15 million European citizens and 1 in 5 people are at risk of developing CHF in their lifetime. It is the leading cause of hospitalizations in patients over 65 years of age, about 1 in 3 patients admitted to hospital will die within one year. CHF accounts for 1-2% (30 Billion €) of healthcare spending in Europe each year. The growth in the numbers of patients developing CHF is driven by the increasing age profile of the EU population and by the growing number of people developing obesity. Early death and rehospitalization can be reduced dramatically, when the progress of the heart disease is monitored continuously with a wireless pressure sensor, permanently implanted in the patient’s left heart ventricle or left atrium. The implant can provide physicians with detailed real-time information about the patient’s vital functions (intra-cardiac pressure, cardiac output and heart rate) around the clock. Based on those readings, the physician can proactively direct the patient to tweak the medication for stabilizing intra-cardiac pressure and provide early personalized treatments to avoid a crisis that would otherwise lead to hospitalization or even death. No mobile system is available, which allows to continuously and wirelessly monitor the patient’s vital functions during normal daily activities, e.g. (house-)work, sports or outdoor use or during sleep time. With the strong backgrounds in medicine, medical technology, nano- and micro fabrication as well as engineering and business background of the consortium the first, ultra-small cardiac pressure sensor implant for mobile, continuous 24-7-readout is investigated to be marketed beginning in phase III. One key for success is the incorporation of novel and proven nano-granular materials, which will be fabricated using a proprietary 3D nanoprinting technique (Nano-3D-Sense™) allowing for outstanding performance in miniaturization, biocompatibility and energy efficiency.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INCA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INCA" are provided by the European Opendata Portal: CORDIS opendata.
Super Productive Line Printing InkjetRead More
A 3D printed, affordable myoelectrical prosthetic hand of personalizeable size for optimal comfort and functionalityRead More
A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.Read More